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with target drugs. The purpose of this study was to ascertain whether revocation of 
the PA requirement resulted in inferior rates of HbA1C testing amongst new users of 
these drugs. METHODS: Data on of new users of the target drugs and on HbA1C
testing in these patients was extracted from EPR databases for the six-month post-
revocation period. The proportion of patients who performed at least one HbA1C test 
during the four months prior to initiation of treatment and 95% conﬁ dence intervals 
were calculated. The data were stratiﬁ ed by month to detect possible trends in rates
of testing during the post policy-change period. RESULTS: After rescinding the PA 
requirement, HbA1C testing amongst incident users of the target drugs dropped from
100% during the PA period to rates of 85.6% (95% CI  79.7, 91.5) to 94.4% (95%
CI  90.8, 97.9). Statistically signiﬁ cant variance in monthly rates of testing was not
observed. CONCLUSIONS: The PA requirement resulted in total performance of a
lab test necessary to monitor drug-therapy outcomes in diabetic patients. When PA is 
implemented as a quality-assurance strategy, revocation should be accompanied by
continuing-education efforts to maintain adherence to recommendations for appropri-
ate care.
PDB53
SHORT-TERM OUTCOMES FOR AN EMPLOYER SPONSERED 
PHARMACIST- PROVIDED MULTI CENTER DIABETES
MANAGEMENT PROGRAM
Pinto S, Kumar J
University of Toledo, Toledo, OH, USA
OBJECTIVES: To measure the impact of pharmacist-provided diabetes management 
program on the economic, clinical, and humanistic outcomes for the City of Toledo
employees and their dependents for a period of 6 months. METHODS: This is a pro-
spective, pre-post longitudinal study. Clinical outcomes collected were A1c, blood
pressure (BP), and body mass index (BMI). These outcomes were measured at the 
baseline, 3 and 6 month visits. Economic outcomes include cost of physician ofﬁ ce
visits, emergency room visits, and inpatients days. These outcomes were measured at 
baseline and 6 month visits. Humanistic outcomes collected were quality of life (using
Sf36v2), patient satisfaction, adherence with medications, and knowledge about dia-
betes. The quality of life and knowledge about diabetes were measured at baseline
and 6 month visits. The patient satisfaction and adherence with medications (using
Morisky scale) were measured at baseline and 3 months visits. Wilcoxon-Signed rank 
test was used to compare variables at two time points. Friedman test was used to
compare variables at multiple time points. Preliminary data analysis for the period 
between baseline visit to 3 months visit is given below. RESULTS: Ninty ﬁ ve patients
have been enrolled to date. Mean A1c’s have decreased signiﬁ cantly from 7.78 at 
baseline visit to 7.44 at 3 months (p  0.05) (N  59). For Intention to treat population 
(baseline A1C  7), the decrease in A1c is even more signiﬁ cant (p  0.01) (N  33). 
Diastolic blood pressure has decreased signiﬁ cantly (p  .001) while systolic blood
pressure and BMI have decreased non-signiﬁ cantly. Self monitoring of blood glucose 
has increased signiﬁ cantly (p  0.01). Patient satisfaction and adherence with medica-
tions has also improved signiﬁ cantly at three-month follow-up visit (p  0.05). Final 
results for the period between baseline visit to 6 months including economic outcomes
will be presented at the ISPOR 14th Annual International Meeting. CONCLUSIONS:
Preliminary data analysis showed that pharmacists can improve the clinical outcomes
in patients with diabetes.
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DULOXETINE THERAPY AND CHANGES IN OPIOID USE AMONG
DIABETIC PERIPHERAL NEUROPATHIC PAIN PATIENTS
Wu N1, Zhao Y2, Boulanger L1, Fraser K1, Chen SY1
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, 
USA
OBJECTIVES: This study examined changes in opioid medication utilization follow-
ing treatment for diabetic peripheral neuropathic pain (DPNP). METHODS: We
studied commercially insured individuals aged 18–64 years who were dispensed dulox-
etine or other DPNP standard of care (SOC) medications (i.e. escitalopram, venlafax-
ine, gabapentin, amitriptyline, or pregabalin) between March 1, 2005 and December 
31, 2005. The dispense date of the initial agent was denoted as the “index date.” 
Patients included were diagnosed with DPNP in the 1 year prior to index and received 
opioids in the prior 90 days. “Duloxetine” and “SOC” cohorts were constructed based
on index agent. Patients in the duloxetine cohort were required to be “continuous” 
users (medication possession ratio q0.8). We assessed changes in long-acting (LA) and
short-acting (SA) opioid utilization one year before and after the index date. Multivari-
ate linear regressions were performed to control for differences in patient demographic 
and clinical characteristics between study cohorts. RESULTS: We identiﬁ ed 97 dulox-
etine patients and 943 SOC patients. Study cohorts were similar in age (mean  55 
years) and proportion female (53%). Over 87% and 20% patients in each cohort were 
dispensed an SA and LA opioid in both the pre- and post-index periods, respectively. 
Hydrocodone was the most common SA opioid, followed by propoxyphene. Oxyco-
done and tramadol were the most common LA opioids. Compared to SOC patients,
continuous duloxetine patients had a greater reduction in days on SA hydrocodone 
(25.8 days, p  0.05), number of SA hydrocodone prescriptions (1.4, p  0.05), and 
days on DPNP-related SA opioids (15.5, p  0.09). Continuous duloxetine users also 
had greater reduction in days on LA oxycodone compared with the SOC patients (8.9, 
p  0.05). CONCLUSIONS: These ﬁ ndings among DPNP patients indicate that con-
tinuous duloxetine users were more likely to have a reduction in use of SA opioids 
and LA oxycodone versus SOC patients.
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UTILIZATION OF ANTIDIABETIC MEDICATIONS OF PATIENTS
WITH TYPE 2 DIABETES COVERED BY VARIOUS TYPES OF HEALTH
INSURANCE IN A US NATIONAL REPRESENTATIVE POPULATION
IN YEAR 2005–2006
Deng L
Quantitative HealthCare Lab, Clinton, NJ, USA
OBJECTIVES: The impact of various medical insurance structures on the quality of 
care is not clearly understood. Drug utilizations patterns of type 2 diabetes patients 
may be affected by health care access, which vary across various types of health insur-
ance and may lead to disparities in disease control and clinical results. METHODS:
A cross-sectional analysis was conducted on data from the National Health and Nutri-
tion Examination Survey (NHANES) 2005–2006. Based on data from survey, patients 
aged 20 years and older with diagnosed type 2 diabetes were classiﬁ ed as patients with
commercial insurance, Medicare and/or Medigap, Medicaid, multiple insurance, other
types of insurance and no health insurance coverage. Likelihood of oral anti-diabetic
medications, insulin or combinations and the likelihood of having successful Glycemic
control were modeled with multi-variables logistic regression analyses with adjustment 
for age, gender, BMI, ethnicity, diabetic complications, household incomes and impor-
tant co-morbidities. RESULTS: A total of 403 diabetic patients were included in the 
analysis. Compared to commercially-insured patients, patients under Medicare (OR 
1.36, 95% CI  0.62, 3.00) or Medicaid (OR  2.32, 95% CI  0.76, 7.04) were more 
likely to be treated with insulin, but less likely to receive oral anti-diabetic medications
(OR  0.19, 95% CI  0.09, 0.40 for Medicare; OR  0.19, 95% CI  0.07, 0.51 for 
Medicaid). The likelihood of having successful glucose control varied but was not
signiﬁ cantly different across types of plans (P  0.05). CONCLUSIONS: Treatment 
patterns varied across various types of health insurance plans and might have impact
on the optimum quality of care and expenditure implications.
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THE EFFECT OF VALUE-BASED INSURANCE DESIGN ON ADHERENCE
TO DIABETES MEDICATIONS: A MATCHED DIFFERENCE IN DIFFERENCE
EVALUATION
Zeng F1, An JJ2, Patel BV1, Scully R3, Barrington C3
1MedImpact Healthcare Systems, Inc., San Diego, CA, USA, 2University of Southern California, 
Los Angeles, CA, USA, 3Health Alliance Medical Plans, Urbana, IL, USA
OBJECTIVES: To evaluate the impact of value-based insurance design (VBID) on 
adherence to diabetic medications. METHODS: Health Alliance Medical Plans of 
Illinois piloted VBID by placing at least one diabetic drug in each class at Tier 1 with 
a $10 copayment for a subgroup of 5400 enrollees in January 2007, while keeping
drug beneﬁ ts unchanged for all other plan enrollees. A matched difference in difference 
method (DID) was used to evaluate the effect of VBID, based on pharmacy claim data. 
Patients with unchanged beneﬁ ts in the same plan were used as the control group.
Patients included in the analysis needed to be continuously enrolled from January
2006 to December 2007 and have used diabetic medications in both years. Adherence
was measured by the proportion of days covered (PDC). A logistic model was used
to model the probability of having PDC  0.8. A 1-to-1 matched control group was 
generated based on propensity score. RESULTS: There were 71 patients in the case
group and 5037 patients in the control group. The matched control group had 71
patients with similar propensity score, baseline characteristics and baseline adherence 
level with the case group. After the implementation of VBID, the average copayment
for diabetic medications decreased from $21.70 to $14.00 for the case group and 
increased from $19.60 to $22.00 for the matched control group. The probability of 
being adherent increased from 69% to 79% for the case group and decreased from
72% to 70% for the matched control group. The matched DID model showed that 
VBID increased the probability of being adherent: OR  1.84, 95% CI: 0.96–3.54, 
p  0.068. The full sample DID estimated OR  1.56 with p  0.065. CONCLUSIONS:
A VBID program that reduced the copayment for diabetic medications by 35%
improved the odds of adherence by 84% and reduced the number of non-adherent
patients by 35%.
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MEDICATION NONADHERENCE AND POTENTIALLY AVOIDABLE 
HOSPITALIZATIONS AMONG PATIENTS WITH DIABETES
Thumula V, Yang Y, Pace PF, Banahan BF, Wilkin NE, Lobb WB
University of Mississippi, University, MS, USA
OBJECTIVES: To examine the association between medication adherence and poten-
tially avoidable hospitalizations (PAHs) among Medicare part D enrollees with dia-
betes. METHODS: A longitudinal retrospective cohort study of 493,609 Medicare 
part D enrollees with diabetes from 6 states (Alabama, California, Florida, Mississippi,
New York and Ohio) who had ﬁ lled at least 1 prescription for oral hypoglycemics, 
angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, and statins.
Adherence was calculated as proportion of days covered for all three classes of medica-
tions using Part D records for the ﬁ rst 6 months of 2006. A summary measure of 
adherence was computed for each patient as an ordinal variable – adherent to none,
any one class, any two classes and all three classes of medications. Medicare part A 
records for the next nine months were used to identify PAHs, as deﬁ ned by the
AHRQ’s Prevention Quality Indicators for diabetes care. Logistic regression was used
to assess the association between nonadherence and PAHs. RESULTS: A total of 
16.2%, 15.7%, 27.3% and 40.8% of patients were adherent with none, any one class, 
any 2 classes and all three classes of medications respectively. A total of 23,222 (4.7%)
patients had at least one PAH, 0.12% had an admission due to diabetes short-term
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complication, 2.8% due to a long-term diabetes complication and 1.9% due to 
uncontrolled diabetes. In logistic regression adjusting for age, sex, race and comorbidi-
ties, nonadherence to all three classes of medications (OR  1.49, 95% CI:1.44–1.55), 
adherence to any 1 class of medications (OR  1.41, 95% CI:1.36–1.47), adherence 
to any 2 classes of medications (OR  1.26, 95% CI:1.21–1.30) were associated with 
higher risks for PAHs compared to adherence with all three classes of medications. 
CONCLUSIONS: Medication adherence is necessary to reduce the risk of PAHs. 
Interventions are needed to improve medication adherence, which will help patients 
realize the full beneﬁ t of hypoglycemic and cardioprotective medications.
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NONADHERENCE TO ORAL HYPOGLYCEMIC AGENTS AND 
POTENTIALLY AVOIDABLE HOSPITALIZATIONS: AN EXAMINATION
OF THE MEDICARE PART D PATIENTS WITH DIABETES
Yang Y, Thumula V, Pace PF, Banahan BF, Wilkin NE, Lobb WB
University of Mississippi, University, MS, USA
OBJECTIVES: To examine the association between nonadherence to oral hypoglyce-
mics and potentially avoidable hospitalizations due to diabetes short-term complica-
tions among Medicare Part D enrollees. METHODS: This is a longitudinal retrospective 
cohort study. Medicare Part D enrollees with diabetes from six states (Alabama, Cali-
fornia, Florida, Mississippi, New York, and Ohio) who had ﬁ lled at least 1 prescription
for oral hypoglycemics during the ﬁ rst half of 2006 were included in the study. Medi-
care Part D claims data for the ﬁ rst 6 months of 2006 were evaluated for adherence
with oral hypoglycemics using proportion of days covered (PDC). Patients were clas-
siﬁ ed as adherent (PDC q 0.8), poor adherent (0.5 a PDC  0.8), and very poor
adherent (0  PDC  0.5). Patients’ Part A records from July 1, 2006 to March 31,
2007 were evaluated for potentially avoidable hospitalizations due to diabetes short-
term complications, one of the diabetes care prevention quality indicators recom-
mended by the Agency for Healthcare Research and Quality. Associations between 
nonadherence and outcomes were assessed using multivariate regression models. 
RESULTS: Data were available for 1,101,533 patients. Among them, 58.4% were
females and the mean age was 71.7 years. About 64.9% were adherent, 11.2% 
were poor adherent, and 24.0% were very poor adherent with oral hypoglycemics. 
Of all patients, 1540 had at least one hospital admissions due to diabetes short-
term complications during the outcome measurement period. After controlling for 
age, gender, race, and comorbidities (Charlson Comorbidity Index), the odds for hos-
pital admission due to diabetes short-term complications was 25.4% (OR: 1.254; 
95%CI: 1.072–1.467) higher for poor adherent patients and 48.0% (OR: 1.480; 
95%CI: 1.326–1.653) higher for very poor adherent patients when compared to 
patients who were adherent to oral hypoglycemics. CONCLUSIONS: Nonadherence 
to oral hypoglycemics is associated with increased risks for potentially avoidable hos-
pitalizations due to diabetes short-term complications. Medicare prescription drug
plans should consider developing targeted interventions to improve adherence to oral
hypoglycemics.
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EFFECT OF CAPITATED MEDICAID HEALTH PLANS ON MEDICATION
ADHERENCE AND HEALTH CARE SERVICE UTILIZATIONS IN TYPE-2 
DIABETES
Pawaskar MD1, Burch SP2, Balkrishnan R3
1Ohio State University College of Pharmacy, Columbus, OH, USA, 2GlaxoSmithKline, 
Research Triangle Park, NC, USA, 3Ohio State University, Columbus, OH, USA
OBJECTIVES: There is a scarcity of the literature evaluating the impact of Medicaid
payment mechanisms on outcomes in diabetes. The objectives of this study was to
examine the impact of Capitated vs. Fee-For-Service (FFS) health plans on medication
adherence and health care service utilizations in type-2 diabetes Medicaid enrollees.
METHODS: A retrospective database study comprised of patients with type-2 diabe-
tes (n  8,581) enrolled in the Medstat MarketScan MultiState Medicaid database
from July 1, 2002 to December 31, 2005. Patients were followed for 6 months before 
and 12 months after the index anti-diabetic medication to collect the data on the
baseline characteristics, medication adherence and health care service utilizations.
Multiple log-linear regression analysis was used to predict medication adherence and
logistic regressions were used to examine the health care service utilizations. RESULTS:
A total of 3763 (44%) of the patients enrolled in capitated plans and 4818 (56%) in 
FFS plans. Patients with capitated plans had 5% lower adherence to anti-diabetes
medications compared to those with FFS plans (5%; P  0.05). Patients with capitated 
health plans had 33% more likelihood of getting hospitalized (OR: 1.33; 95% CI: 
1.17, 1.49) and 16% increased odds of having ER visit as compared to those with 
FFS (OR: 1.16; 95% CI: 1.06, 1.28). Further, 10% increase in medication adherence 
was associated with 7% decreased in the odds of hospitalizations (OR: 0.53; 95%CI:
0.46, 0.66) and 6% decreased in the odds of ER visits (OR: 0.48; 95% CI: 0.40, 0.55).
CONCLUSIONS: Patients with capitated health plans had signiﬁ cant lower medica-
tion adherence and also associated with signiﬁ cantly higher health care service utiliza-
tions. Capitated managed care plans may not be cost effective for the long term
management of chronic conditions such as diabetes.
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ASSESSMENT OF THE INTERVAL BETWEEN FIRST EXENATIDE CLAIM
AND LAST PRIOR ORAL ANTIDIABETIC CLAIM
Misurski D1, Quimbo RA2, Hou L2, Pawaskar MD1, Wade R3
1Eli Lilly and Company, Indianapolis, IN, USA, 2HealthCore, Inc., Wilmington, DE, USA, 
3HealthCore, Inc., Wilmington, DC, USA
OBJECTIVES: Access to prescription drugs may be controlled by formulary step edits. 
Speciﬁ c criteria are sometimes set by insurers for drug coverage. Exenatide coverage
may require previous prescriptions for oral antidiabetics (OAD), typically either met-
formin (MET), sulfonylureas (SULF) or thiazolidediones (TZD) within speciﬁ c inter-
vals or “look-back windows”. These typically range from 60 to 180 days. This analysis
assessed the timing of OAD claims prior to initiation of exenatide. METHODS: Data 
were obtained from the HealthCore Integrated Research DatabaseTM. Adult patients
had a claim for exenatide between May 1, 2005 and March 31, 2008, q12 months 
pre-index eligibility, and a type-2 diabetes diagnosis (N  22,533). RESULTS: A pre-
index OAD claim was present for 20,228 (95%) patients. The mean (oSD) duration 
for any previous claim of either MET, SULF or TZD was 60 o 116. For MET, SULF
and TZD individually, durations were 95 o 168, 116 o 202, and 135 o 200 days,
respectively. For patients q65 years (n  2301) the mean (oSD) duration for any previ-
ous claim for either MET, SULF or TZD was 63 o 114 days and for MET, SULF and 
TZD individually, durations were 110 o 174, 104 o 169, and 144 o 199 days, respec-
tively. Of the entire cohort 6280 (28%) did not have a claim for MET, SULF or TZD
within 60 days of exenatide. Of those with an OAD claim, 3975 (20%) did not have
a claim for MET, SULF or TZD within 60 days. CONCLUSIONS: These data repre-
sent only successfully adjudicated exenatide claims. Plans in this database may have 
had OAD step edits in place at some time during the study period. For plans with no
OAD step edits, mean durations may have been longer and the percent of patients 
with ﬁ lls after 60 days higher. This analysis supports careful consideration of look-
back window durations. Overly restrictive intervals (i.e., 60 days) may inappropriately
exclude patients from receiving exenatide.
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HEALTH CARE COSTS AND UTILIZATION ASSOCIATED WITH
TREATMENT MODIFICATION IN TYPE-2 DIABETES MELLITUS (T2DM) 
PATIENTS TAKING ORAL ANTI-DIABETIC DRUGS (OADS)
Krishnarajah G1, Bhosle MJ2, Chapman R2
1Bristol-Myers Squibb, Princeton, NJ, USA, 2IMS Health, Falls Church, VA, USA
OBJECTIVES: To provide the optimal beneﬁ t-risk proﬁ le, OADs must be appropri-
ately titrated and, often, used in combination. We compared overall health care utiliza-
tion and costs among diabetic patients who added a new OAD medication to initial 
therapy and those with up-titration of initial OAD METHODS: Insurance claims data 
were obtained from ~90 health plans for patients age q18 years with diagnosis of 
T2DM based on q2 ICD-9 claims during the period January 1, 2001–June 30, 2007
and newly prescribed metformin or sulfonylurea monotherapy regimen lasting q90 
days. Patients with type-1 or gestational diabetes, or OAD use within 180 days prior,
were excluded. Patients (N  22,917) were followed after initiation of monotherapy
to identify occurrence of ﬁ rst treatment modiﬁ cation (addition or up-titration). Study 
outcomes were analyzed during one year after ﬁ rst treatment modiﬁ cation. RESULTS:
Overall, 27% of patients (n  6,191) had a new OAD added to their initial OAD, 
while 73% of patients (n  16,726) had initial OAD up-titrated. During the post-
treatment modiﬁ cation period, all medication costs for the addition cohort were higher 
than for the up-titration cohort [mean (SD), median  $4618.67 ($8313.00), $2870.73 
vs. $4004.19 ($8158.37), $2188.345; p  0.0001] but total health care costs were 
lower [$8157.41 (16771.09), $4264.44 vs. $8447.33 (20281.44), $4764.17; p 
0.0001], largely due to lower costs for inpatient admissions [$1641.76 ($10124.90), 
$1647.73 vs. $1960.42 ($13363.90), $1819.10; p  0.0002]. In a multivariable model
adjusting for prior health care expenditure, demographic and clinical variables, total 
costs of new OAD addition remained signiﬁ cantly lower than costs of initial OAD 
up-titration [$9568 vs. $10027.13; p  0.048]. CONCLUSIONS: Up-titration of 
initial OAD therapy was associated with higher subsequent total health care costs 
than addition of another OAD, perhaps due to limited incremental efﬁ cacy when up-
titrating beyond intermediate doses. When appropriate, physicians should consider
adding an OAD rather than up-titrating the current OAD.
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THE IMPACT OF PHARMACISTS INTERVENTIONS ON OUTCOMES OF
DIABETIC PATIENTS COMPARED TO USUAL CARE
Johnson KA, Chen S, Cheng IN, Lou M, McCombs JS
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To evaluate the effect of pharmacist interventions on diabetic patient
outcomes compared to usual care without pharmacist clinical intervention. 
METHODS: The study was implemented in “Safety Net” clinics located in Los 
Angeles County serving poor, Hispanic patients. Pharmacist services included review 
of the patient’s medical and medication history, medication evaluation and adjust-
ments or deletions under an established protocol, ordering and reviewing routine labo-
ratory tests [e.g., HbA1c levels, LDL, HDL, etc.], monitoring patient compliance, 
patient education and scheduling follow-up visits. Control patients were selected ret-
rospectively to match the intervention cohort. The primary outcome was measured as 
the reduction of A1c and the percentage of patients who achieved the treatment goal, 
an A1c 7%. Secondary outcomes focused on the diabetes-related outcomes, a
decreased in blood pressure, lipid levels and BMI. METHODS:: Multiple linear regres-
